MX2023008955A - Compuesto inhibidor de tyk2 que contiene anillo biciclico. - Google Patents

Compuesto inhibidor de tyk2 que contiene anillo biciclico.

Info

Publication number
MX2023008955A
MX2023008955A MX2023008955A MX2023008955A MX2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A MX 2023008955 A MX2023008955 A MX 2023008955A
Authority
MX
Mexico
Prior art keywords
compound containing
bicyclic ring
inhibitor compound
containing bicyclic
tyk2 inhibitor
Prior art date
Application number
MX2023008955A
Other languages
English (en)
Inventor
Bin Wang
Hongjiang Xu
Fei Liu
Yanlong Liu
Xujing Tang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023008955A publication Critical patent/MX2023008955A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto inhibidor de TYK2 que contiene un anillo bicíclico y su uso en la preparación de un fármaco para tratar o prevenir enfermedades relacionadas con TYK2.
MX2023008955A 2021-02-06 2022-01-30 Compuesto inhibidor de tyk2 que contiene anillo biciclico. MX2023008955A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110165856 2021-02-06
CN202110935764 2021-08-16
CN202111063960 2021-09-10
CN202210056272 2022-01-18
PCT/CN2022/075145 WO2022166917A1 (zh) 2021-02-06 2022-01-30 含联环的tyk2抑制剂化合物

Publications (1)

Publication Number Publication Date
MX2023008955A true MX2023008955A (es) 2023-09-29

Family

ID=82740880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008955A MX2023008955A (es) 2021-02-06 2022-01-30 Compuesto inhibidor de tyk2 que contiene anillo biciclico.

Country Status (11)

Country Link
US (1) US20240182446A1 (es)
EP (1) EP4289833A1 (es)
JP (1) JP2024505912A (es)
KR (1) KR20230143611A (es)
CN (1) CN116783178A (es)
AU (1) AU2022216727A1 (es)
CA (1) CA3209830A1 (es)
IL (1) IL304766A (es)
MX (1) MX2023008955A (es)
TW (1) TW202233600A (es)
WO (1) WO2022166917A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2922846T3 (en) * 2012-11-08 2019-01-21 Bristol Myers Squibb Co AMID-SUBSTITUTED HETEROCYCLIC COMPOUNDS USED AS MODULATORS OF IL-12, IL-23 AND / OR IFN-ALPHA
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
KR20210086674A (ko) * 2018-10-30 2021-07-08 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
EP4143180A1 (en) * 2020-04-28 2023-03-08 Bristol-Myers Squibb Company Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators

Also Published As

Publication number Publication date
WO2022166917A1 (zh) 2022-08-11
CN116783178A (zh) 2023-09-19
KR20230143611A (ko) 2023-10-12
US20240182446A1 (en) 2024-06-06
IL304766A (en) 2023-09-01
CA3209830A1 (en) 2022-08-11
EP4289833A1 (en) 2023-12-13
TW202233600A (zh) 2022-09-01
AU2022216727A1 (en) 2023-09-07
JP2024505912A (ja) 2024-02-08

Similar Documents

Publication Publication Date Title
PH12019501744A1 (en) Methods for the administration of certain vmat2 inhibitors
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
HUP0400782A2 (hu) Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények
HK1075422A1 (en) Use of il-18 inhibitors in the manufacture of medicaments
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021012418A (es) Compuestos heterociclicos y sus usos.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021013318A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
CR20220374A (es) Métodos de tratamiento de la esplenomegalia
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
MX2023008955A (es) Compuesto inhibidor de tyk2 que contiene anillo biciclico.
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
EP4236944A4 (en) BICYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF DISEASES
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
NZ751972A (en) Treatment of prurigo nodularis
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
MX2022011711A (es) Compuesto de oxofenilarsina deuterada y uso del mismo.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2023003583A (es) Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.